<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01149252</url>
  </required_header>
  <id_info>
    <org_study_id>Psoriasis</org_study_id>
    <nct_id>NCT01149252</nct_id>
  </id_info>
  <brief_title>Determination of the Efficacy and Safety of Psoralait Versus Placebo in the Treatment of Psoriasis</brief_title>
  <official_title>Determination of the Efficacy and Safety of Psoralait Versus Placebo in the Treatment of Psoriasis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trima, Israel Pharmaceutical Products</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Trima, Israel Pharmaceutical Products</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficacy of a new product,&#xD;
      Psoralait, as compared to a placebo in the treatment of psoriasis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulties arouse in recruiting new patients&#xD;
  </why_stopped>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Psoriasis Area and Severity Index (PASI).</measure>
    <time_frame>After four weeks of treatment.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dermatology Life Quality Index (DLQI).</measure>
    <time_frame>After four weeks of treatment.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Psoralait</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Psoralait</intervention_name>
    <description>Cream to be used as instructed.</description>
    <arm_group_label>Psoralait</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo cream.</intervention_name>
    <description>Cream to be used as instructed</description>
    <arm_group_label>Psoralait</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who have been clinically diagnosed as suffering from psoriasis and are or&#xD;
             aren't scheduled for Narrow Band Ultraviolet B (UVB)phototherapy of affected&#xD;
             areas,excluding face and genitalia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant, lactating, planning to become pregnant, or women of&#xD;
             child-bearing potential who have not successfully been using the same medically&#xD;
             acceptable contraceptive methods over the previous 3 months, e.g., oral contraceptive&#xD;
             agents, intrauterine device (IUD) and barrier method plus spermicide.&#xD;
&#xD;
          -  Use of topical anti psoriatic therapy (including topical retinoids, corticosteroids,&#xD;
             or vitamin D analogs) on the areas to be treated within 2 weeks prior to the beginning&#xD;
             of the study.&#xD;
&#xD;
          -  Received systemic biologic therapy to treat psoriasis (for example: alefacept,&#xD;
             etanercept, infliximab, adalimumab) within 12 weeks prior to the beginning of the&#xD;
             study.&#xD;
&#xD;
          -  Received systemic psoriasis therapy (for example: methotrexate, cyclosporine, systemic&#xD;
             corticosteroids, retinoids such as acitretin) within 4 weeks prior to the beginning of&#xD;
             the study.&#xD;
&#xD;
          -  Received phototherapy (including laser), photo chemotherapy or climatotherapy within 4&#xD;
             weeks prior to the beginning of the study.&#xD;
&#xD;
          -  Recent history (within past 12 months) of alcohol or substance abuse. Alcohol abuse&#xD;
             will be defined as &gt;14 drinks per week (1 drink = 12 oz beer, 4 oz wine, or 1.5 oz&#xD;
             distilled spirits).&#xD;
&#xD;
          -  History of noncompliance to medical regimens or unwilling to comply with the study&#xD;
             protocol.&#xD;
&#xD;
          -  Participation in an investigational drug study within 30 days prior to the beginning&#xD;
             of the study.&#xD;
&#xD;
          -  Serious or unstable medical or psychological conditions that in the opinion of the&#xD;
             Investigator would compromise the subject's safety or successful participation in the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Phototherapy and Dermatology Day Care Center, Sheba Medical Center, Tel Hashomer</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>June 20, 2010</study_first_submitted>
  <study_first_submitted_qc>June 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2010</study_first_posted>
  <last_update_submitted>December 16, 2014</last_update_submitted>
  <last_update_submitted_qc>December 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

